Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; |
| 21.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 10.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | incorporated by reference into this Item 3.02. Item 5.02. Departure of Directors or Certain Officers; Election of Dir |
| 08.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 25.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tion 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 17.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 09.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
Stammdaten
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Evelo Biosciences, Inc. |
|---|---|
| Ticker | EVLO |
| CIK | 0001694665 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1.898 USD |
| Beta | 0,62 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2023-09-30 | 10-Q | -12,364,000 | -0.71 | 20,627,000 | -26,707,000 | |
| 2023-06-30 | 10-Q | -21,103,000 | -3.78 | 20,819,000 | -46,126,000 | |
| 2023-03-31 | 10-Q | -25,341,000 | -0.23 | 41,970,000 | -27,388,000 | |
| 2022-12-31 | 10-K | -114,527,000 | -1.31 | 64,441,000 | -4,992,000 | |
| 2022-09-30 | 10-Q | -30,564,000 | -5.66 | 86,336,000 | 9,334,000 | |
| 2022-06-30 | 10-Q | -30,561,000 | -8.07 | 111,901,000 | 35,648,000 | |
| 2022-03-31 | 10-Q | -29,861,000 | -0.56 | 58,825,000 | -16,802,000 | |
| 2021-12-31 | 10-K | -122,176,000 | -2.31 | 87,871,000 | 8,667,000 | |
| 2021-09-30 | 10-Q | -33,730,000 | -0.63 | 116,458,000 | 33,076,000 | |
| 2021-06-30 | 10-Q | -31,598,000 | -0.59 | 145,058,000 | 62,093,000 | |
| 2021-03-31 | 10-Q | -28,196,000 | -0.55 | 153,042,000 | 87,839,000 | |
| 2020-12-31 | 10-K | -93,666,000 | -2.37 | 90,639,000 | 30,485,000 | |
| 2020-09-30 | 10-Q | -20,923,000 | -0.45 | 104,837,000 | 50,430,000 | |
| 2020-06-30 | 10-Q | -20,652,000 | -0.63 | 113,905,000 | 69,206,000 | |
| 2020-03-31 | 10-Q | -23,041,000 | 83,147,000 | 39,344,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.